A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal CD4+CD25+CD127lo/-FOXP3+ Regulatory T-cells [Tregs]) in Adolescents with Recent Onset Type 1 Diabetes Mellitus (T1DM) v: 7.0; 17-Jan-2017
Primary Objective
Assess the safety and potential efficacy of CLBS03 to modify the T1DM disease course, including preservation of a-cell function and improvements in measures of disease severity, as compared with placebo, in adolescents with recent onset T1DM.
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Barbara Davis Center
UCD Barbara Davis Center
Study ID
Protocol Number: 16-0905
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers